Pharma Pulse 11/5/24: Alternative Targeting Methods in a Post-Cookie World, Future Modalities for Infertility & more

Promising Alternative Targeting Methods in a Post-Cookie World

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explores the most promising alternative targeting methods that advertisers can adopt in a post-cookie world, and how they compare to traditional approaches.

Future Modalities for Infertility

Lucy van de Wiel, PhD, discusses how emerging technologies such as in vitro gametogenesis and gene editing show promise for addressing complex infertility cases, potentially revolutionizing reproductive medicine by offering new solutions for patients with genetic disorders, same-sex couples, and those with uterine factor infertility.

The Giant Supercomputer Built to Transform an Entire Country—and Paid For by Ozempic

The world’s latest AI machine is powered by the success of two products: Nvidia’s chips and Novo Nordisk’s weight-loss drugs.

Omada Health Publishes Findings from Consumer Survey of GLP-1 Users, Revealing Majority Discontinue the Drug Before Reaching Their Goal Weight

Omada Health released findings from an attitudinal survey of 1,000 non-Omada members to better understand the needs of consumers taking GLP-1 medications for weight loss. The survey focused on the impact of GLP-1s throughout the patient journey, assessing individuals' feelings and experiences before, during, and after taking the popular weight loss medications.

Jeffery Bernstein on LinkedIn
Here is the 2nd of my 3 part interview withPharmaceutical Commerce Magazine. This segment touches on the dominance of human error, ransomware and wire fraud/BEC in healthcare. Many thanks to those following along!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs